Next Article in Journal
Biogenic Silver Nanoparticles Produced by Soil Rare Actinomycetes and Their Significant Effect on Aspergillus-derived mycotoxins
Next Article in Special Issue
Antimicrobial Resistance of Campylobacter coli Isolated from Caecal Samples of Fattening Pigs at Slaughter
Previous Article in Journal
Rosenbergiella meliponini D21B Isolated from Pollen Pots of the Australian Stingless Bee Tetragonula carbonaria
Previous Article in Special Issue
In-Package Atmospheric Cold Plasma Treatment and Storage Effects on Membrane Integrity, Oxidative Stress, and Esterase Activity of Listeria monocytogenes
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Defined Pig Microbiota with a Potential Protective Effect against Infection with Salmonella Typhimurium

1
Department of Microbiology, Nutrition and Dietetics, Faculty of Agrobiology, Food and Natural Resources, Czech University of Life Sciences Prague, 165 00 Prague, Czech Republic
2
Laboratory of Gnotobiology, Institute of Microbiology, Czech Academy of Sciences, 549 22 Novy Hradek, Czech Republic
3
Laboratory of Anaerobic Microbiology, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, 142 20 Prague, Czech Republic
*
Author to whom correspondence should be addressed.
Microorganisms 2023, 11(4), 1007; https://doi.org/10.3390/microorganisms11041007
Submission received: 9 March 2023 / Revised: 4 April 2023 / Accepted: 7 April 2023 / Published: 12 April 2023
(This article belongs to the Special Issue Foodborne Pathogens and Antimicrobial Resistance)

Abstract

:
A balanced microbiota is a main prerequisite for the host’s health. The aim of the present work was to develop defined pig microbiota (DPM) with the potential ability to protect piglets against infection with Salmonella Typhimurium, which causes enterocolitis. A total of 284 bacterial strains were isolated from the colon and fecal samples of wild and domestic pigs or piglets using selective and nonselective cultivation media. Isolates belonging to 47 species from 11 different genera were identified by MALDI-TOF mass spectrometry (MALDI-TOF MS). The bacterial strains for the DPM were selected for anti-Salmonella activity, ability to aggregate, adherence to epithelial cells, and to be bile and acid tolerant. The selected combination of 9 strains was identified by sequencing of the 16S rRNA gene as Bacillus sp., Bifidobacterium animalis subsp. lactis, B. porcinum, Clostridium sporogenes, Lactobacillus amylovorus, L. paracasei subsp. tolerans, Limosilactobacillus reuteri subsp. suis, and Limosilactobacillus reuteri (two strains) did not show mutual inhibition, and the mixture was stable under freezing for at least 6 months. Moreover, strains were classified as safe without pathogenic phenotype and resistance to antibiotics. Future experiments with Salmonella-infected piglets are needed to test the protective effect of the developed DPM.

1. Introduction

The gastrointestinal (GI) tract represents the most extensive interface between the host, environmental factors, and antigens in the human body. During the lifetime, a large amount of food passes through the digestive tract, together with microorganisms from the environment, which pose a considerable threat to the integrity of the gut [1]. The GI microbiota represents trillions of microbes adhering to the intestinal wall or occurring loosely in the lumen of the intestine [2]. It is highly individual [3] and is composed of more than 4000 different prokaryotes [4], but also viruses, archaea, and eukarya are present [5]. Furthermore, the GI microbiota has co-evolved with the host [6] to form a complex symbiotic relationship ranging from mutualism to parasitism [7,8].
GI microbiota has many functions, including converting indigestible food residues, production of short-chain fatty acids and vitamins, stimulating immune responses, and formation of barriers against pathogenic microorganisms [9]. Commensal bacteria can affect the host’s health beneficially or detrimentally [10]. For example, a balanced microbiota promotes resistance to intestinal pathogens [11] and protects against overgrowth with indigenous pathobionts (opportunistic pathogens) [12,13]. On the other hand, pathogens developed strategies to escape colonization resistance mediated by commensal microorganisms and used them for their profit [14,15]. Therefore, the interplay between pathogens, commensals, or indigenous pathobionts is decisive for controlling infectious diseases. Understanding the interactions between pathogens and commensal microorganisms can lead to new therapeutic approaches and the treatment of infectious diseases [12].
Among the most common intestinal pathogens worldwide belong to Salmonella enterica serovar Typhimurium (S. typhimurium), which affects both the small and large intestines [16] and causes enterocolitis in humans, pigs, and other warm-blooded animals [17]. Annually 200,000 people die from salmonellosis caused by non-typhoidal Salmonella spp. It is typically characterized by a self-limiting gastroenteritis syndrome expressed by anorexia, diarrhea, fever, and vomiting [18]. S. typhimurium also can cause life-threatening illnesses in immunocompromised hosts [19]. In swine, Salmonella strains cause septicemia, enterocolitis, or subclinical infections [20]. The enterocolitis form associated with S. typhimurium has low mortality and high morbidity [21], with the signs described above. Subclinical forms do not cause disease but may be associated with reduced productivity and average daily gain [22], and increased risk of food contamination [23]. Livestock farms, in general, are a significant source of salmonellosis [24]. Feed antibiotics, banned in the European Union [25], were used to limit intestinal infections in farm animals as prevention in the past [26]. One of the promising possibilities to suppress infections with enteric pathogens, and favorably influence the composition of the intestinal microbiota and stimulate the host immune response, can be the use of defined multispecies synthetic microbiota composed of host-specific strains. Such microbiota support colonization resistance as a result of mutual interactions between the host and its original microbes and microbes and each other [27,28,29]. Probiotics are considered to be well-tolerated and safe and are selected to exhibit potential health benefits to the host through modulation of the gut microbiota [30], e.g., as the prevention of nosocomial [31] and antibiotic-associated diarrhoea [32], management of acute gastroenteritis symptoms [33], reduction of the eczema incidence [34], alleviation of lactose intolerance [35], and protection against gut dysbiosis associated with learning and memory disorders [36]. Beneficial effects are exerted through a variety of mechanisms, including the production of bacteriocins, lowering gut pH and colonization, invading pathogenic organisms, and modifying the immune response, viability, and activity of passage through the GI tract [37] where probiotics must survive the unfavorable conditions of the environment [30]. Commercial probiotics with a non-specific effect on the host are often used in animal and human nutrition [38].
To select new probiotic strains with specific and required properties, in vitro assays are commonly used as a screening tool to identify potential probiotic properties [39,40,41]. Probiotics’ functionality is then verified using in vivo systems with laboratory or farm animals [42]. Interestingly, there are the most often used mice experiments [42] because the availability of mutant and genetically modified mouse strains greatly facilitates functional studies [43]. These studies use human bacteria to colonize gnotobiotic mice, although there are phylogenetic differences between them. The human [44] and mouse [45] microbiota are divergent, and they can influence microbe–host interactions and the long-term stability of colonization [46]. In contrast, human [44] and pig [47] microbiomes show high similarities. Moreover, pigs show close anatomic, physiologic, and genetic similarities to humans, and results obtained from pig models should be more plausibly translated to humans [48].
Our study aimed to screen the anti-Salmonella potential of pig bacterial isolates and develop probiotic-defined pig microbiota with functional and technologically desired properties for future use as a novel protective strategy against the infection with Salmonella Typhimurium in in vivo systems.

2. Materials and Methods

2.1. Bacterial Strain Isolation

The broad spectra of commensal bacteria were isolated from colon and fecal samples of pigs/piglets bred in Czech farms (n = 25, samples taken at slaughterhouses) and wild boars (n = 25, samples collected during hunting). Samples were collected in tubes containing 5 g/L tryptone, 5 g/L nutrient broth No. 2, 2.5 g/L yeast extract (all Oxoid, Basingstoke, UK), 0.5 g/L L-cysteine, 1 mL/L tween 80 (both Sigma-Aldrich, St. Louis, MO, USA), and 30% glycerol (V.W.R., Radnor, PA, USA). After the sample collection and transfer to the place of analysis, log 10 serial dilutions of samples were plated on different media cultivated under various cultivation conditions (Table 1).
Bacterial isolates were obtained based on different cultivation characteristics of colonies from all used media. The oxygen, temperature, and substrate requirements were secured for the following sub-cultivation. Anaerobes were cultured in Wilkins–Chalgren Anaerobe broth supplemented with soya pepton (5 g/L; both Oxoid), L-cysteine (0.5 g/L), and tween 80 (1 mL/L, both Sigma-Aldrich), while aerobes in Tryptone Soya broth (Oxoid), both for 24 h. Then, bacterial isolates were stored as stock cultures at −80 °C in 30% glycerol.

2.2. Culture Identifications

Bacterial isolates were identified by MALDI-TOF mass spectrometry (MALDI-TOF MS) with ethanol-formic acid extraction procedure with HCCA matrix solution according to the manufacturer’s instructions (Bruker Daltonik GmbH, Bremen, Germany) with the usage of an extended custom database in Biotyper software (Bruker) for identification of bifidobacteria [50].
Based on species variability, the selected isolates were then identified by 16S rRNA gene amplicon sequencing. DNA was isolated using PrepMan Ultra™ (Applied Biosystems, Waltham, MA, USA) according to the manufacturer’s instructions. For PCR amplifications of the 16S rRNA gene, the universal pair of primers fD1/rP2 [51] was used, except for pair 285F/261R [52] for the identification of bifidobacteria. PCR products were purified by the EZNA Cycle Pure Kit (Omega Bio-Tek, Norcross, GA, USA) and sequenced by Eurofins Genomics (Ebersberg, Germany). The obtained sequences were processed in Chromas Lite 2.5.1 (Technelysium Pty Ltd., Tewantin, Australia), BioEdit [53] with ClustalW algorithm [54], and compared with 16S rRNA gene sequences in BLAST rRNA/ITS (https://blast.ncbi.nlm.nih.gov/https://www.ezbiocloud.net/, accessed on 4 November 2022) and EZBioCloud databases (https://www.ezbiocloud.net/, accessed on 4 November 2022).

2.3. Characterization of In Vitro Potentially Probiotic Properties

The antimicrobial activity of cell-free supernatants from all isolated pig commensal bacteria was tested against streptomycin-sensitive wild-type Salmonella Typhimurium LT2 [55] and its streptomycin-resistant mutant (STM) [56] on Tryptone Soya agar (Oxoid) by the agar-well diffusion method in triplicates. In the second step, the activity of neutralized supernatant was determined [57].
Isolates were grouped into two phenotypes in relation to auto-aggregation ability (Agg). Strains were forming sand-like particles by aggregated cells gravitating to the bottom of tubes (if cultivated in liquid media), resulting in a clear solution of media (Agg+) and bacteria without Agg ability (Agg−), producing constant turbidity for a long time. Moreover, Agg ability was expressed as a percentage (%) after the procedure described elsewhere [58].
Properties predicting the survival of commensal bacteria during passage through the animal GI tract were tested using the method described by [59]. After the incubation of tested strains in PBS buffer adjusted with HCl (Sigma-Aldrich) to pH 2 or containing 1.5% of bile extract (Oxoid), the residual viable counts were determined by standard plate count on appropriate media. Then, the antibiotic resistance/sensitivity assay was performed using a disc diffusion method under conditions determined by EUCAST [60]. For the interpretation of zone diameters, the breakpoint tables were used (Version 11.0, 2021, http://www.eucast.org). Phenotypic tests associated with a pathogenic potential of Bacillus spp. were performed. Hemolytic activity was determined by plating a freshly grown culture on Columbia Blood agar (Oxoid) supplemented with 5% sheep blood (v/v, Oxoid) according to [61]. To assess lecithinase activity, the freshly grown cultures were plated on Tryptone Soya agar enriched with a sterile egg yolk emulsion (100 mL/L, Oxoid) [62].

2.4. Adherence to the Porcine IPEC-J2 Cell Line

Strains with Agg phenotype and representatives from isolated genera were tested for the adhesion to intestinal cell lines in triplicates. The bacterial adhesion methods previously described by [63] were used with some modifications. The intestinal porcine epithelial IPEC-J2 (ACC 701) cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). For the visualization of adhered bacteria, the fluorescein isothiocyanate (Life Technologies, Carlsbad, CA, USA) was used with a final concentration 25 μg/mL. The staining procedure took 30 min at 37 °C in the dark. Fluorescence was then measured using Tecan Infinite M200 (Tecan Group, Männedorf, Switzerland) at an excitation wavelength of 495 nm and emission wavelength of 519 nm. The percentage (%) of adherent bacteria was calculated as described elsewhere [64].

2.5. Preparation of Defined Pig Microbiota (DPM) and Its Stability

The mutual inhibition of the strains selected for DPM was tested by the agar-well diffusion method as described above. Then, the strains were co-cultured in appropriate broth, and their numbers were determined by the standard plate counts technique after the cultivation in the mixture or as a single strain. Overnight bacterial cultures were collected by centrifugation (12,000× g, 4 °C, 5 min), resuspended in PBS buffer, and centrifuged again to completely remove cultivation media. After that, all bacterial strains were resuspended in PBS buffer with 30% glycerol and mixed to a final concentration of 5 × 108 CFU/mL (approximately 5.50 × 107 CFU/mL for each strain). All procedures were carried out under anaerobic conditions (Bugbox, BioTrace, Bridgend, UK). The mixture was aliquoted into cryovials in final volume 1.2 mL (6 × 108 CFU/mL), and single doses of stock cultures were stored at −28 °C and −80 °C. Bacterial mixture stability was determined by cultivation on media described in Table 1, after 1 day, then 1, 3, and 6 months of storage. Three single doses were used for each determination. The identity of re-isolated strains was verified by MALDI-TOF MS [50].

2.6. Statistics

Bacterial mixture stability and viability (cultivation counts in log CFU/mL) were evaluated using StatSoft, Inc. (2013) (STATISTICA—data analysis software system, version 12, www.statsoft.com) and MS Excel (Redmond, WA, USA). The normality of the data was assessed by the Shapiro–Wilk W test (α = 0.05). Differences within the storage temperature were evaluated using a t-test (α = 0.05), and differences within the time duration of storage by one-way ANOVA (α = 0.05).

2.7. Ethical Approval

The work with animals was conducted according to the ethical standards defined by the EU legislation on the use of experimental animals (2010/63/EU) and approved by the Animal Care and Use Committee of the Czech Academy of Sciences (protocol 57/2021; 18 August 2021).

3. Results

3.1. Bacterial Isolation and Identification

A total of 284 bacterial strains were isolated from the colon and fecal samples of wild and domestic pigs or piglets. The isolates belonged to 47 species from 11 different genera as determined by MALDI-TOF MS (Table 2).
The identity of strains selected for DPM was verified by the 16S rRNA gene sequencing (Table 3). Bacteria were identified as Bacillus sp. (Bacillus paramycoides/paranthracis/nitratireducens identification group), Bifidobacterium animalis subsp. lactis, Bifidobacterium porcinum, Clostridium sporogenes, Lactobacillus amylovorus, Lactobacillus paracasei subsp. tolerans, Limosilactobacillus reuteri subsp. suis, and the next two Limosilactobacillus reuteri strains that were further indistinguishable at the subspecies level (kinnaridis/murium/porcinus/rodentium/suis) by used methods.

3.2. Characterization of In Vitro Potentially Probiotic Properties

One hundred and fifteen cell-free supernatants inhibited the growth of Salmonella strains. Inhibition zones ranged from 7.00 to 13.33 mm, 9.23 ± 1.29 mm on average (Table 3 and Table S1). The most active isolates belonged to Lactobacillaceae family and genera Bifidobacterium, Enterococcus, and Clostridium. No anti-Salmonella activity was observed for strains of genera Acidaminococcus, Bacillus, Bacteroides, Escherichia, Paeniclostridium, Paraclostridium, Streptococcus, Staphylococcus, and Terrisporobacter. The pH values of active cell-free supernatants varied between 3.5 and 4.1. The neutralized supernatants did not inhibit tested Salmonella strains. The pH of non-active supernatants reached neutral or slightly acid values.
Eighty strains with anti-Salmonella activity and/or the ability to adhere to epithelial cells were tested for the properties predicting their survival ability in the gastrointestinal tract (Table 3 and Table S1). In general, the tested bacteria were more sensitive to 1.5% bile extract than to low pH, but obtained results are highly strain-specific. Forty-two of 80 strains tested showed excellent bile tolerance (<1 log CFU/mL decrease in viability) after 3 h of incubation. Twenty-two isolates showed a decrease in viability even lower than 0.25 log CFU/mL. The survival of commensal bacteria at low pH was slightly better than in 1.5% bile extract. Fifty-one showed a decrease in viability lower than 1 log CFU/mL at pH 3 after 2 h of incubation and counts of 26 strains did not decrease under 0.25 log CFU/mL.
None of the tested strains was resistant to antibiotics, according to EUCAST breakpoint tables. After the cultivation of Bacillus spp. on agar containing blood, neither clear nor green zones were detected, and strains were considered non-hemolytic. Strain B. licheniformis PC2 showed a slight lecithinase activity after the cultivation on the agar with egg yolk. No precipitation zones were observed in the other two tested Bacillus strains.

3.3. Auto-Aggregation and Adherence to the Porcine IPEC-J2 Cell Line

Agg phenotype was just observed in some strains of Bifidobacterium spp. and Lactobacillaceae and varied between 21.83 and 78.00%. The adhesion to epithelial cell lines was predominantly determined in strains with Agg phenotype but the representatives from each isolated genus were also tested. Bacteria adhered to porcine epithelial cell line IPEC-J2 in a range from 0.21 ± 0.08% to 17.42 ± 2.22 (Table 3 and Table S1). Agg phenotype was not always in correlation with adherence capacity.

3.4. Defined Pig Microbiota and Its Stability

Based on tested properties, in the final, 9 strains (Table 3) were selected for DPM preparation with a potential protective effect against Salmonella infections suitable for future application to gnotobiotic piglets. The bacteria did not inhibit each other in their growth as determined by the agar-well diffusion method and standard plate counts technique after their co-cultivation. The stability of the bacterial mixture was verified on 1 day and after 1, 3, and 6 months of freezing at −28 °C and −80 °C by the cultivation. An initial concentration of 5 × 108 CFU/mL was maintained throughout the whole storage period with total numbers oscillating between 5.89 × 108 to 7.79 × 108 CFU/mL, not depending on storage temperature without statistically significant differences in both monitored parameters. The MALDI-TOF MS analysis confirmed the presence of all included bacterial species in each analyzed dose.

4. Discussion

There are various ways to realize microbiota-based therapy, such as fecal microbiota transplantation, diet and probiotics, synthetic microbiota, and microbiota-derived bioactive compounds [65]. A mono-association of germ-free piglets [66] with commensal pig bifidobacteria [67,68] and lactobacilli [69] mildly alleviated signs of S. typhimurium-caused enterocolitis. A comparison of the protective effect of three well-known probiotics Bifidobacterium animalis subsp. lactis BB-12 [70], Lactobacillus rhamnosus GG [71], and Escherichia coli Nissle 1917 [67,69] caused amelioration of the subsequent infection with S. typhimurium, as well. However, the protection was highly significant only in E. coli Nissle 1917 [69]. A more complex effect of multistrain microbiota on the host is possible to expect [72,73]. Thus, current probiotic preparations are usually composed of several bacterial species/strains.
A Bristol microbiota was derived from Altered Schaedler Flora microbiota composed of three murine bacterial species. After it was applied to hysterectomy-derived GF piglets, it was able to colonize the piglet gut without any deleterious effect on piglets [74]. However, it is known that the association of the GI tract with species-specific microbiota is more effective than microbiota derived from different species [75]. Unfortunately, commercial probiotics currently used to modify animal intestinal microbiota have non-specified effects on the host, and their colonization ability is limited. Thus, these feed supplements may not have the desired health effect [76]. Furthermore, in addition to this lack of guaranteed outcomes, there may be no less significant problem of product viability during administration in farm conditions [77]. Commonly used probiotic microbes in pig production often consists only of enterococci [78] and a few bacterial strains [79]. It would be desirable to administer a broader spectrum of microorganisms to achieve the targeted effect. Bifidobacteria [80] and lactobacilli [81], which commonly inhabit the pig intestines, thus also could be promising as probiotics for pigs. Therefore, if the aim of the probiotic application is to suppress salmonellosis, it is advisable to use a bacterium or a bacterial mixture with a proven effect against Salmonella. Experiments with farm animals usually consist in feeding non-specific probiotic strains and then monitoring the effect on the performance of the animals [82]. On the contrary, an approach chosen in our work was precisely targeted. We aimed to develop specific DPM from pig origin strains with the potential ability to protect piglets against infection with Salmonella Typhimurium.
Recently, a collection of bacterial GI commensals isolated from the pig GI tract consisting of 110 species across 40 families and nine phyla have been introduced [83]. It reveals many taxonomic groups with specific metabolic functions and probiotic potential for pigs. Similarly, we cultured a wide variety of different bacterial strains and tested their potential probiotic properties and anti-Salmonella effect. In our study, almost 300 isolates of 47 species belonging to 11 genera were isolated from colon and fecal samples of wild and domestic pigs or piglets. The commensals suitable for preparing a DPM with a potential protective effect against intestinal infections were chosen primarily based on their antimicrobial activity against Salmonella Typhimurium strains and their prerequisite for colonization of the gut. When cultivated under laboratory conditions, it was found that some strains of potentially probiotic genera Acidaminococcus, Eubacterium, and Mitsuokella cannot be kept alive. Therefore, further analyses with these isolates could not be performed. Our results showed that cell-free supernatant from nearly half of the tested bacteria, including Lactobacillaceae, Bifidobacterium, Enterococcus, and Clostridium strains, has antimicrobial activity against Salmonella LT2 and its streptomycin-resistant mutant. Since the neutralized cell-free supernatant did not inhibit Salmonella strains, antimicrobial activity is caused especially by a decrease in pH by the production of organic acids [84]. A reduction in the antagonistic effect of cell-free supernatants from potentially probiotic strains after its neutralization was also reported in the study of Tejero-Sariñena et al. [85]. However, the production of other antibacterial compounds cannot be excluded. Secretion of specific antimicrobial peptides and proteins by commensal bacteria was reported elsewhere [86,87,88]. Inhibitory activity of various putative probiotic strains against S. typhimurium and other intestinal pathogens was reported in many studies [89,90,91].
In synergy with the production of antimicrobial substances, colonization resistance is an important mechanism in host protection [11]. So, the bacterial consortium had to be able to adhere to the intestinal mucosa and colonize the intestines [92]. Moreover, strains with high adhesive properties may play a role in colonizing the mucosa with enteropathogens through competitive and binding sites on the intestinal epithelium, providing more health benefits. It can emphasize the local action of some metabolites that are produced by probiotic bacteria [93]. Some studies have reported that adhesion ability may correlate closely with auto-aggregation [94]. This fact was not fully confirmed in our study. There were some strains with strong auto-aggregation phenotypes which were not able to adhere to the porcine IPEC-J2 cell line. On the other hand, some isolates showing zero auto-aggregation capacity strongly adhered to epithelia. A presumption for successful colonization of the intestine is survival ability during the passage through the host’s upper parts of the GI tract [30]. In our experiment, many strains showed excellent low pH and bile tolerance and did not decrease in viability by more than 0.25 log CFU/mL. Similar results were reported by [95,96]. In general, the pig-origin strains tested in our study were slightly more sensitive to bile extract than to low pH. These results are in contrast with our previous studies, where calf- and lamb-origin strains were tested and showed higher sensitivity to low pH [57,97].
Well-identified bacterial strains for a mixture with a potentially protective effect against Salmonella infection were selected. Our DPM composed of 9 strains showed the following properties: either anti-Salmonella activity or adherence capacity, tolerance to low pH and bile extract, non-pathogenic phenotype, absence of antibiotic resistance and mutual inhibition, and stability during storage under freezing conditions for a long time duration. These characteristics are standardly used for testing bacteria with potential probiotic effects [98,99] but have only predictive value.
Probiotics are usually applied in an inactive form as spray-dried, frozen, or freeze-dried. Moreover, all these variants have been verified as suitable for preservation and distribution [100]. In the study of Geigerova et al. [101], it was proven that the preservation form of probiotics does not affect their ability to colonize the intestine. Similarly to Darnaud et al. [102], we used freezing as a preservation method for its simplicity and the long-term survival of all strains of newly developed DPM in this form.
There are numerous studies using minimally defined microbiota in gnotobiotic models [27,46]. Furthermore, well-characterized strains are usually used but without previous testing for their mutual interactions [102]. In our study, bacteria were selected according to functional properties, and their mutual interactions were emphasized. Our approach increases the probability of successful colonization of all bacteria from the consortia.

5. Conclusions

Based on the in vitro results, the mixture of nine commensal bacteria with anti-Salmonella activity was developed for possible application to piglets. Selected bacteria which were able to adhere to epithelial cells, were bile and acid tolerant, classified as safe without pathogenic phenotype and resistance to antibiotics, did not show mutual inhibition, and had favorable technological properties. Nevertheless, future experiments with gnotobiotic and conventional piglets are needed to verify the protective effect of the bacterial consortium in vivo.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms11041007/s1, Table S1: Identification and functional properties of commensal bacteria isolated from pig and piglet colon and fecal samples.

Author Contributions

Conceptualization, I.S., N.M. and E.V.; methodology, K.H., I.S., N.M., A.S., I.D. and E.V.; validation, N.M. and E.V.; formal analysis, I.S.; investigation, A.A., E.I., J.K., R.P. and T.K.; resources, E.V.; data curation, K.H., N.M., J.K. and E.V.; writing—original draft preparation, K.H., I.S., N.M., A.S. and E.V.; writing—review and editing, I.S., N.M. and E.V.; visualization, E.V. and I.S.; supervision, E.V.; project administration, E.V.; funding acquisition, E.V. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded by grants 21-15621S of the Czech Science Foundation, and the Institutional Research Concept RVO 61388971 of the Institute of Microbiology of the Czech Academy of Sciences.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are available upon request from the corresponding author.

Acknowledgments

We are grateful to Jana Machova, Hana Sychrovska, and Katerina Polakova for their excellent technical support.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Thursby, E.; Juge, N. Introduction to the Human Gut Microbiota. Biochem. J. 2017, 474, 1823–1836. [Google Scholar] [CrossRef] [PubMed]
  2. Donaldson, G.P.; Lee, S.M.; Mazmanian, S.K. Gut Biogeography of the Bacterial Microbiota. Nat. Rev. Microbiol. 2016, 14, 20–32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Beller, L.; Deboutte, W.; Falony, G.; Vieira-Silva, S.; Tito, R.Y.; Valles-Colomer, M.; Rymenans, L.; Jansen, D.; Van Espen, L.; Papadaki, M.I.; et al. Successional Stages in Infant Gut Microbiota Maturation. mBio 2021, 12, e0185721. [Google Scholar] [CrossRef] [PubMed]
  4. Almeida, A.; Nayfach, S.; Boland, M.; Strozzi, F.; Beracochea, M.; Shi, Z.J.; Pollard, K.S.; Sakharova, E.; Parks, D.H.; Hugenholtz, P.; et al. A Unified Catalog of 204,938 Reference Genomes from the Human Gut Microbiome. Nat. Biotechnol. 2021, 39, 105–114. [Google Scholar] [CrossRef] [PubMed]
  5. Macpherson, A.J.; McCoy, K.D. Standardised Animal Models of Host Microbial Mutualism. Mucosal Immunol. 2015, 8, 476–486. [Google Scholar] [CrossRef] [Green Version]
  6. Derrien, M.; Alvarez, A.-S.; de Vos, W.M. The Gut Microbiota in the First Decade of Life. Trends Microbiol. 2019, 27, 997–1010. [Google Scholar] [CrossRef] [Green Version]
  7. Sekirov, I.; Russell, S.L.; Antunes, L.C.M.; Finlay, B.B. Gut Microbiota in Health and Disease. Physiol. Rev. 2010, 90, 859–904. [Google Scholar] [CrossRef] [Green Version]
  8. Swain Ewald, H.A.; Ewald, P.W. Natural Selection, The Microbiome, and Public Health. Yale J. Biol. Med. 2018, 91, 445–455. [Google Scholar]
  9. Krautkramer, K.A.; Fan, J.; Bäckhed, F. Gut Microbial Metabolites as Multi-Kingdom Intermediates. Nat. Rev. Microbiol. 2021, 19, 77–94. [Google Scholar] [CrossRef]
  10. Metwaly, A.; Reitmeier, S.; Haller, D. Microbiome Risk Profiles as Biomarkers for Inflammatory and Metabolic Disorders. Nat. Rev. Gastroenterol. Hepatol. 2022, 19, 383–397. [Google Scholar] [CrossRef]
  11. Ducarmon, Q.R.; Zwittink, R.D.; Hornung, B.V.H.; van Schaik, W.; Young, V.B.; Kuijper, E.J. Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection. Microbiol. Mol. Biol. Rev. 2019, 83, e00007-19. [Google Scholar] [CrossRef] [PubMed]
  12. Kamada, N.; Chen, G.Y.; Inohara, N.; Núñez, G. Control of Pathogens and Pathobionts by the Gut Microbiota. Nat. Immunol. 2013, 14, 685–690. [Google Scholar] [CrossRef]
  13. Zeng, M.Y.; Inohara, N.; Nuñez, G. Mechanisms of Inflammation-Driven Bacterial Dysbiosis in the Gut. Mucosal Immunol. 2017, 10, 18–26. [Google Scholar] [CrossRef] [Green Version]
  14. Faber, F.; Thiennimitr, P.; Spiga, L.; Byndloss, M.X.; Litvak, Y.; Lawhon, S.; Andrews-Polymenis, H.L.; Winter, S.E.; Bäumler, A.J. Respiration of Microbiota-Derived 1,2-Propanediol Drives Salmonella Expansion during Colitis. PLoS Pathog. 2017, 13, e1006129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Maier, L.; Vyas, R.; Cordova, C.D.; Lindsay, H.; Schmidt, T.S.B.; Brugiroux, S.; Periaswamy, B.; Bauer, R.; Sturm, A.; Schreiber, F.; et al. Microbiota-Derived Hydrogen Fuels Salmonella Typhimurium Invasion of the Gut Ecosystem. Cell Host Microbe 2013, 14, 641–651. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Zhang, S.; Kingsley, R.A.; Santos, R.L.; Andrews-Polymenis, H.; Raffatellu, M.; Figueiredo, J.; Nunes, J.; Tsolis, R.M.; Adams, L.G.; Bäumler, A.J. Molecular Pathogenesis of Salmonella enterica Serotype Typhimurium-Induced Diarrhea. Infect. Immun. 2003, 71, 1–12. [Google Scholar] [CrossRef] [Green Version]
  17. Campos, J.; Mourão, J.; Peixe, L.; Antunes, P. Non-Typhoidal Salmonella in the Pig Production Chain: A Comprehensive Analysis of Its Impact on Human Health. Pathogens 2019, 8, 19. [Google Scholar] [CrossRef] [Green Version]
  18. Crump, J.A.; Sjölund-Karlsson, M.; Gordon, M.A.; Parry, C.M. Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections. Clin. Microbiol. Rev. 2015, 28, 901–937. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Wen, S.C.; Best, E.; Nourse, C. Non-Typhoidal Salmonella Infections in Children: Review of Literature and Recommendations for Management. J. Paediatr. Child Health 2017, 53, 936–941. [Google Scholar] [CrossRef]
  20. Nair, S.; Farzan, A.; O’Sullivan, T.L.; Friendship, R.M. Time Course of Salmonella Shedding and Antibody Response in Naturally Infected Pigs during Grower-Finisher Stage. Can. J. Vet. Res. 2018, 82, 139–145. [Google Scholar]
  21. Fedorka-Cray, P.J.; Gray, J.T.; Wray, C. Salmonella Infections in Pigs. In Salmonella in Domestic Animals; CABI International: Wallingford, UK, 2000; pp. 191–207. [Google Scholar]
  22. Farzan, A.; Friendship, R.M. A Clinical Field Trial to Evaluate the Efficacy of Vaccination in Controlling Salmonella Infection and the Association of Salmonella-Shedding and Weight Gain in Pigs. Can. J. Vet. Res. 2010, 74, 258–263. [Google Scholar]
  23. Naberhaus, S.A.; Krull, A.C.; Arruda, B.L.; Arruda, P.; Sahin, O.; Schwartz, K.J.; Burrough, E.R.; Magstadt, D.R.; Matias Ferreyra, F.; Gatto, I.R.H.; et al. Pathogenicity and Competitive Fitness of Salmonella enterica Serovar 4,[5],12:i:- Compared to Salmonella Typhimurium and Salmonella Derby in Swine. Front Vet Sci. 2019, 6, 502. [Google Scholar] [CrossRef] [Green Version]
  24. Velasquez, C.G.; Macklin, K.S.; Kumar, S.; Bailey, M.; Ebner, P.E.; Oliver, H.F.; Martin-Gonzalez, F.S.; Singh, M. Prevalence and Antimicrobial Resistance Patterns of Salmonella Isolated from Poultry Farms in Southeastern United States. Poult. Sci. 2018, 97, 2144–2152. [Google Scholar] [CrossRef]
  25. Millet, S.; Maertens, L. The European Ban on Antibiotic Growth Promoters in Animal Feed: From Challenges to Opportunities. Vet. J. 2011, 187, 143–144. [Google Scholar] [CrossRef] [PubMed]
  26. Castanon, J.I.R. History of the Use of Antibiotic as Growth Promoters in European Poultry Feeds. Poult. Sci. 2007, 86, 2466–2471. [Google Scholar] [CrossRef]
  27. Brugiroux, S.; Beutler, M.; Pfann, C.; Garzetti, D.; Ruscheweyh, H.-J.; Ring, D.; Diehl, M.; Herp, S.; Lötscher, Y.; Hussain, S.; et al. Genome-Guided Design of a Defined Mouse Microbiota That Confers Colonization Resistance against Salmonella enterica Serovar Typhimurium. Nat. Microbiol. 2016, 2, 16215. [Google Scholar] [CrossRef]
  28. Stecher, B. Establishing Causality in Salmonella-Microbiota-Host Interaction: The Use of Gnotobiotic Mouse Models and Synthetic Microbial Communities. Int. J. Med. Microbiol. 2021, 311, 151484. [Google Scholar] [CrossRef] [PubMed]
  29. Lee, H.; Ko, G. Antiviral Effect of Vitamin A on Norovirus Infection via Modulation of the Gut Microbiome. Sci. Rep. 2016, 6, 25835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Shi, L.H.; Balakrishnan, K.; Thiagarajah, K.; Mohd Ismail, N.I.; Yin, O.S. Beneficial Properties of Probiotics. Trop Life Sci. Res. 2016, 27, 73–90. [Google Scholar] [CrossRef]
  31. Hojsak, I.; Szajewska, H.; Canani, R.B.; Guarino, A.; Indrio, F.; Kolacek, S.; Orel, R.; Shamir, R.; Vandenplas, Y.; van Goudoever, J.B.; et al. Probiotics for the Prevention of Nosocomial Diarrhea in Children. J. Pediatr. Gastroenterol. Nutr. 2018, 66, 3–9. [Google Scholar] [CrossRef]
  32. Guo, Q.; Goldenberg, J.Z.; Humphrey, C.; El Dib, R.; Johnston, B.C. Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea. Cochrane Database Syst. Rev. 2019, 4, CD004827. [Google Scholar] [CrossRef]
  33. Szajewska, H.; Guarino, A.; Hojsak, I.; Indrio, F.; Kolacek, S.; Shamir, R.; Vandenplas, Y.; Weizman, Z. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Use of Probiotics for Management of Acute Gastroenteritis: A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 531–539. [Google Scholar] [CrossRef] [Green Version]
  34. Schmidt, R.M.; Pilmann Laursen, R.; Bruun, S.; Larnkjaer, A.; Mølgaard, C.; Michaelsen, K.F.; Høst, A. Probiotics in Late Infancy Reduce the Incidence of Eczema: A Randomized Controlled Trial. Pediatr. Allergy Immunol. 2019, 30, 335–340. [Google Scholar] [CrossRef] [PubMed]
  35. Oak, S.J.; Jha, R. The Effects of Probiotics in Lactose Intolerance: A Systematic Review. Crit. Rev. Food Sci. Nutr. 2019, 59, 1675–1683. [Google Scholar] [CrossRef] [PubMed]
  36. Roy Sarkar, S.; Mitra Mazumder, P.; Banerjee, S. Probiotics Protect against Gut Dysbiosis Associated Decline in Learning and Memory. J. Neuroimmunol. 2020, 348, 577390. [Google Scholar] [CrossRef] [PubMed]
  37. Kligler, B.; Cohrssen, A. Probiotics. Am. Fam. Physician. 2008, 78, 1073–1078. [Google Scholar]
  38. Bhogoju, S.; Nahashon, S. Recent Advances in Probiotic Application in Animal Health and Nutrition: A Review. Collect. FAO Agric. 2022, 12, 304. [Google Scholar] [CrossRef]
  39. Ishibashi, N.; Yamazaki, S. Probiotics and Safety. Am. J. Clin. Nutr. 2001, 73, 465S–470S. [Google Scholar] [CrossRef] [Green Version]
  40. Kailasapathy, K.; Chin, J. Survival and Therapeutic Potential of Probiotic Organisms with Reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol. Cell Biol. 2000, 78, 80–88. [Google Scholar] [CrossRef]
  41. Papadimitriou, K.; Zoumpopoulou, G.; Foligné, B.; Alexandraki, V.; Kazou, M.; Pot, B.; Tsakalidou, E. Discovering Probiotic Microorganisms: In Vitro, in Vivo, Genetic and Omics Approaches. Front. Microbiol. 2015, 6, 58. [Google Scholar] [CrossRef] [Green Version]
  42. Taylor, K.; Gordon, N.; Langley, G.; Higgins, W. Estimates for Worldwide Laboratory Animal Use in 2005. Altern. Lab. Anim. 2008, 36, 327–342. [Google Scholar] [CrossRef] [Green Version]
  43. Eppig, J.T.; Blake, J.A.; Bult, C.J.; Kadin, J.A.; Richardson, J.E. Mouse Genome Database Group The Mouse Genome Database (MGD): Facilitating Mouse as a Model for Human Biology and Disease. Nucleic Acids Res. 2015, 43, D726–D736. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T.; et al. A Human Gut Microbial Gene Catalogue Established by Metagenomic Sequencing. Nature 2010, 464, 59–65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Xiao, L.; Feng, Q.; Liang, S.; Sonne, S.B.; Xia, Z.; Qiu, X.; Li, X.; Long, H.; Zhang, J.; Zhang, D.; et al. A Catalog of the Mouse Gut Metagenome. Nat. Biotechnol. 2015, 33, 1103–1108. [Google Scholar] [CrossRef] [PubMed]
  46. Eberl, C.; Ring, D.; Münch, P.C.; Beutler, M.; Basic, M.; Slack, E.C.; Schwarzer, M.; Srutkova, D.; Lange, A.; Frick, J.S.; et al. Reproducible Colonization of Germ-Free Mice With the Oligo-Mouse-Microbiota in Different Animal Facilities. Front. Microbiol. 2019, 10, 2999. [Google Scholar] [CrossRef]
  47. Xiao, L.; Estellé, J.; Kiilerich, P.; Ramayo-Caldas, Y.; Xia, Z.; Feng, Q.; Liang, S.; Pedersen, A.Ø.; Kjeldsen, N.J.; Liu, C.; et al. A Reference Gene Catalogue of the Pig Gut Microbiome. Nat Microbiol 2016, 1, 16161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Lunney, J.K.; Van Goor, A.; Walker, K.E.; Hailstock, T.; Franklin, J.; Dai, C. Importance of the Pig as a Human Biomedical Model. Sci. Transl. Med. 2021, 13, eabd5758. [Google Scholar] [CrossRef] [PubMed]
  49. Vlková, E.; Salmonová, H.; Bunešová, V.; Geigerová, M.; Rada, V.; Musilová, Š. A New Medium Containing Mupirocin, Acetic Acid, and Norfloxacin for the Selective Cultivation of Bifidobacteria. Anaerobe 2015, 34, 27–33. [Google Scholar] [CrossRef] [PubMed]
  50. Modrackova, N.; Stovicek, A.; Burtscher, J.; Bolechova, P.; Killer, J.; Domig, K.J.; Neuzil-Bunesova, V. The Bifidobacterial Distribution in the Microbiome of Captive Primates Reflects Parvorder and Feed Specialization of the Host. Sci. Rep. 2021, 11, 15273. [Google Scholar] [CrossRef]
  51. Weisburg, W.G.; Barns, S.M.; Pelletier, D.A.; Lane, D.J. 16S Ribosomal DNA Amplification for Phylogenetic Study. J. Bacteriol. 1991, 173, 697–703. [Google Scholar] [CrossRef] [Green Version]
  52. Kim, B.J.; Kim, H.-Y.; Yun, Y.-J.; Kim, B.-J.; Kook, Y.-H. Differentiation of Bifidobacterium Species Using Partial RNA Polymerase {beta}-Subunit (RpoB) Gene Sequences. Int. J. Syst. Evol. Microbiol. 2010, 60, 2697–2704. [Google Scholar] [CrossRef] [Green Version]
  53. Hall, T.A. BioEdit: A User-Friendly Biological Sequence Alignment Editor and Analysis Program for Windows 95/98/NT. In Nucleic Acids Symposium; 41 Edn 95–98; Information Retrieval Ltd.: London, UK, 1999. [Google Scholar]
  54. Thompson, J.D.; Higgins, D.G.; Gibson, T.J. CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice. Nucleic Acids Res. 1994, 22, 4673–4680. [Google Scholar] [CrossRef] [Green Version]
  55. McClelland, M.; Sanderson, K.E.; Spieth, J.; Clifton, S.W.; Latreille, P.; Courtney, L.; Porwollik, S.; Ali, J.; Dante, M.; Du, F.; et al. Complete Genome Sequence of Salmonella enterica Serovar Typhimurium LT2. Nature 2001, 413, 852–856. [Google Scholar] [CrossRef] [Green Version]
  56. Trebichavský, I.; Dlabac, V.; Reháková, Z.; Zahradnícková, M.; Splíchal, I. Cellular Changes and Cytokine Expression in the Ilea of Gnotobiotic Piglets Resulting from Peroral Salmonella Typhimurium Challenge. Infect. Immun. 1997, 65, 5244–5249. [Google Scholar] [CrossRef] [Green Version]
  57. Vlková, E.; Grmanová, M.; Rada, V.; Homutová, I.; Dubná, S. Selection of Probiotic Bifidobacteria for Lambs. Czech J. Anim. Sci. 2009, 54, 552–565. [Google Scholar] [CrossRef] [Green Version]
  58. Del Re, B.; Sgorbati, B.; Miglioli, M.; Palenzona, D. Adhesion, Autoaggregation and Hydrophobicity of 13 Strains of Bifidobacterium Longum. Lett. Appl. Microbiol. 2000, 31, 438–442. [Google Scholar] [CrossRef] [PubMed]
  59. Saarela, M.; Hallamaa, K.; Mattila-Sandholm, T.; Mättö, J. The Effect of Lactose Derivatives Lactulose, Lactitol and Lactobionic Acid on the Functional and Technological Properties of Potentially Probiotic Lactobacillus Strains. Int. Dairy J. 2003, 13, 291–302. [Google Scholar] [CrossRef]
  60. Matuschek, E.; Brown, D.F.J.; Kahlmeter, G. Development of the EUCAST Disk Diffusion Antimicrobial Susceptibility Testing Method and Its Implementation in Routine Microbiology Laboratories. Clin. Microbiol. Infect. 2014, 20, O255–O266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  61. Hollensteiner, J.; Wemheuer, F.; Harting, R.; Kolarzyk, A.M.; Diaz Valerio, S.M.; Poehlein, A.; Brzuszkiewicz, E.B.; Nesemann, K.; Braus-Stromeyer, S.A.; Braus, G.H.; et al. Bacillus Thuringiensis and Bacillus Weihenstephanensis Inhibit the Growth of Phytopathogenic Verticillium Species. Front. Microbiol. 2016, 7, 2171. [Google Scholar] [CrossRef] [Green Version]
  62. Kushner, D.J. An Evaluation of the Egg-Yolk Reaction as a Test for Lecithinase Activity. J. Bacteriol. 1957, 73, 297–302. [Google Scholar] [CrossRef] [Green Version]
  63. Krausova, G.; Hyrslova, I.; Hynstova, I. In Vitro Evaluation of Adhesion Capacity, Hydrophobicity, and Auto-Aggregation of Newly Isolated Potential Probiotic Strains. Fermentation 2019, 5, 100. [Google Scholar] [CrossRef] [Green Version]
  64. Xu, H.; Lao, L.; Ji, C.; Lu, Q.; Guo, Y.; Pan, D.; Wu, Z. Anti-Inflammation and Adhesion Enhancement Properties of the Multifunctional LPxTG-Motif Surface Protein Derived from the Lactobacillus Reuteri DSM 8533. Mol. Immunol. 2022, 146, 38–45. [Google Scholar] [CrossRef] [PubMed]
  65. Sorbara, M.T.; Pamer, E.G. Microbiome-Based Therapeutics. Nat. Rev. Microbiol. 2022, 20, 365–380. [Google Scholar] [CrossRef]
  66. Splichalova, A.; Slavikova, V.; Splichalova, Z.; Splichal, I. Preterm Life in Sterile Conditions: A Study on Preterm, Germ-Free Piglets. Front. Immunol. 2018, 9, 220. [Google Scholar] [CrossRef] [Green Version]
  67. Splichalova, A.; Trebichavsky, I.; Rada, V.; Vlkova, E.; Sonnenborn, U.; Splichal, I. Interference of Bifidobacterium Choerinum or Escherichia Coli Nissle 1917 with Salmonella Typhimurium in Gnotobiotic Piglets Correlates with Cytokine Patterns in Blood and Intestine. Clin. Exp. Immunol. 2011, 163, 242–249. [Google Scholar] [CrossRef] [PubMed]
  68. Splichalova, A.; Pechar, R.; Killer, J.; Splichalova, Z.; Bunesova, V.N.; Vlkova, E.; Salmonova, H.S.; Splichal, I. Colonization of Germ-Free Piglets with Mucinolytic and Non-Mucinolytic Bifidobacterium Boum Strains Isolated from the Intestine of Wild Boar and Their Interference with Salmonella Typhimurium. Microorganisms 2020, 8, 2002. [Google Scholar] [CrossRef]
  69. Splichal, I.; Donovan, S.M.; Jenistova, V.; Splichalova, I.; Salmonova, H.; Vlkova, E.; Neuzil Bunesova, V.; Sinkora, M.; Killer, J.; Skrivanova, E.; et al. High Mobility Group Box 1 and TLR4 Signaling Pathway in Gnotobiotic Piglets Colonized/Infected with L. Amylovorus, L. Mucosae, E. coli Nissle 1917 and S. typhimurium. Int. J. Mol. Sci. 2019, 20, 6294. [Google Scholar] [CrossRef] [Green Version]
  70. Splichalova, A.; Donovan, S.M.; Tlaskalova-Hogenova, H.; Stranak, Z.; Splichalova, Z.; Splichal, I. Monoassociation of Preterm Germ-Free Piglets with Bifidobacterium Animalis Subsp. Lactis BB-12 and Its Impact on Infection with Salmonella Typhimurium. Biomedicines 2021, 9, 183. [Google Scholar] [CrossRef]
  71. Splichalova, A.; Jenistova, V.; Splichalova, Z.; Splichal, I. Colonization of Preterm Gnotobiotic Piglets with Probiotic Lactobacillus Rhamnosus GG and Its Interference with Salmonella Typhimurium. Clin. Exp. Immunol. 2019, 195, 381–394. [Google Scholar] [CrossRef]
  72. Dominici, L.; Moretti, M.; Villarini, M.; Vannini, S.; Cenci, G.; Zampino, C.; Traina, G. In Vivo Antigenotoxic Properties of a Commercial Probiotic Supplement Containing Bifidobacteria. Int. J. Probiotics Prebiotics 2011, 6, 4. [Google Scholar]
  73. Roselli, M.; Pieper, R.; Rogel-Gaillard, C.; de Vries, H.; Bailey, M.; Smidt, H.; Lauridsen, C. Immunomodulating Effects of Probiotics for Microbiota Modulation, Gut Health and Disease Resistance in Pigs. Anim. Feed Sci. Technol. 2017, 233, 104–119. [Google Scholar] [CrossRef] [Green Version]
  74. Laycock, G.; Sait, L.; Inman, C.; Lewis, M.; Smidt, H.; van Diemen, P.; Jorgensen, F.; Stevens, M.; Bailey, M. A Defined Intestinal Colonization Microbiota for Gnotobiotic Pigs. Vet. Immunol. Immunopathol. 2012, 149, 216–224. [Google Scholar] [CrossRef]
  75. McCracken, V.J.; Lorenz, R.G. The Gastrointestinal Ecosystem: A Precarious Alliance among Epithelium, Immunity and Microbiota. Cell. Microbiol. 2001, 3, 1–11. [Google Scholar] [CrossRef]
  76. Zmora, N.; Zilberman-Schapira, G.; Suez, J.; Mor, U.; Dori-Bachash, M.; Bashiardes, S.; Kotler, E.; Zur, M.; Regev-Lehavi, D.; Brik, R.B.-Z.; et al. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell 2018, 174, 1388–1405.e21. [Google Scholar] [CrossRef] [Green Version]
  77. Barba-Vidal, E.; Martín-Orúe, S.M.; Castillejos, L. Practical Aspects of the Use of Probiotics in Pig Production: A Review. Livest. Sci. 2019, 223, 84–96. [Google Scholar] [CrossRef]
  78. Simon, O. Micro-Organisms as Feed Additives—Probiotics. Adv. Pork Prod. 2005, 16, 161–167. [Google Scholar]
  79. Markowiak, P.; Śliżewska, K. The Role of Probiotics, Prebiotics and Synbiotics in Animal Nutrition. Gut Pathog. 2018, 10, 21. [Google Scholar] [CrossRef] [PubMed]
  80. Pechar, R.; Killer, J.; Mekadim, C.; Geigerová, M.; Rada, V. Classification of Culturable Bifidobacterial Population from Colonic Samples of Wild Pigs (Sus Scrofa) Based on Three Molecular Genetic Methods. Curr. Microbiol. 2017, 74, 1324–1331. [Google Scholar] [CrossRef]
  81. Yang, J.; Qian, K.; Wang, C.; Wu, Y. Roles of Probiotic Lactobacilli Inclusion in Helping Piglets Establish Healthy Intestinal Inter-Environment for Pathogen Defense. Probiotics Antimicrob. Proteins 2018, 10, 243–250. [Google Scholar] [CrossRef]
  82. Anadón, A.; Ares, I.; Martínez-Larrañaga, M.R.; Martínez, M.A. Prebiotics and Probiotics in Feed and Animal Health. In Nutraceuticals in Veterinary Medicine; Gupta, R.C., Srivastava, A., Lall, R., Eds.; Springer International Publishing: Cham, Switzerland, 2019; pp. 261–285. ISBN 9783030046248. [Google Scholar]
  83. Wylensek, D.; Hitch, T.C.A.; Riedel, T.; Afrizal, A.; Kumar, N.; Wortmann, E.; Liu, T.; Devendran, S.; Lesker, T.R.; Hernández, S.B.; et al. A Collection of Bacterial Isolates from the Pig Intestine Reveals Functional and Taxonomic Diversity. Nat. Commun. 2020, 11, 6389. [Google Scholar] [CrossRef]
  84. Yamano, T.; Iino, H.; Takada, M.; Blum, S.; Rochat, F.; Fukushima, Y. Improvement of the Human Intestinal Flora by Ingestion of the Probiotic Strain Lactobacillus Johnsonii La1. Br. J. Nutr. 2006, 95, 303–312. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Tejero-Sariñena, S.; Barlow, J.; Costabile, A.; Gibson, G.R.; Rowland, I. In Vitro Evaluation of the Antimicrobial Activity of a Range of Probiotics against Pathogens: Evidence for the Effects of Organic Acids. Anaerobe 2012, 18, 530–538. [Google Scholar] [CrossRef] [PubMed]
  86. Kanmani, P.; Satish Kumar, R.; Yuvaraj, N.; Paari, K.A.; Pattukumar, V.; Arul, V. Probiotics and Its Functionally Valuable Products-a Review. Crit. Rev. Food Sci. Nutr. 2013, 53, 641–658. [Google Scholar] [CrossRef] [PubMed]
  87. Li, Y.; Xiang, Q.; Zhang, Q.; Huang, Y.; Su, Z. Overview on the Recent Study of Antimicrobial Peptides: Origins, Functions, Relative Mechanisms and Application. Peptides 2012, 37, 207–215. [Google Scholar] [CrossRef]
  88. Simons, A.; Alhanout, K.; Duval, R.E. Bacteriocins, Antimicrobial Peptides from Bacterial Origin: Overview of Their Biology and Their Impact against Multidrug-Resistant Bacteria. Microorganisms 2020, 8, 639. [Google Scholar] [CrossRef]
  89. Makras, L.; Triantafyllou, V.; Fayol-Messaoudi, D.; Adriany, T.; Zoumpopoulou, G.; Tsakalidou, E.; Servin, A.; De Vuyst, L. Kinetic Analysis of the Antibacterial Activity of Probiotic Lactobacilli towards Salmonella enterica Serovar Typhimurium Reveals a Role for Lactic Acid and Other Inhibitory Compounds. Res. Microbiol. 2006, 157, 241–247. [Google Scholar] [CrossRef]
  90. Shi, S.; Qi, Z.; Sheng, T.; Tu, J.; Shao, Y.; Qi, K. Antagonistic Trait of Lactobacillus Reuteri S5 against Salmonella Enteritidis and Assessment of Its Potential Probiotic Characteristics. Microb. Pathog. 2019, 137, 103773. [Google Scholar] [CrossRef]
  91. Ozogul, F.; Yazgan, H.; Ozogul, Y. Lactic Acid Bacteria: Lactobacillus Acidophilus. In Encyclopedia of Dairy Sciences; Academic Press: Cambridge, MA, USA, 2022; pp. 187–197. [Google Scholar]
  92. Thakur, N.; Rokana, N.; Panwar, H. Probiotics, Selection Criteria, Safety and Role in Health And. J. Innov. Biol. Jan. 2016, 3, 259–270. [Google Scholar]
  93. Monteagudo-Mera, A.; Rastall, R.A.; Gibson, G.R.; Charalampopoulos, D.; Chatzifragkou, A. Adhesion Mechanisms Mediated by Probiotics and Prebiotics and Their Potential Impact on Human Health. Appl. Microbiol. Biotechnol. 2019, 103, 6463–6472. [Google Scholar] [CrossRef] [Green Version]
  94. MacKenzie, D.A.; Jeffers, F.; Parker, M.L.; Vibert-Vallet, A.; Bongaerts, R.J.; Roos, S.; Walter, J.; Juge, N. Strain-Specific Diversity of Mucus-Binding Proteins in the Adhesion and Aggregation Properties of Lactobacillus Reuteri. Microbiology 2010, 156, 3368–3378. [Google Scholar] [CrossRef] [Green Version]
  95. Feng, Y.; Qiao, L.; Liu, R.; Yao, H.; Gao, C. Potential Probiotic Properties of Lactic Acid Bacteria Isolated from the Intestinal Mucosa of Healthy Piglets. Ann. Microbiol. 2017, 67, 239–253. [Google Scholar] [CrossRef]
  96. Tulumoglu, S.; Yuksekdag, Z.N.; Beyatli, Y.; Simsek, O.; Cinar, B.; Yaşar, E. Probiotic Properties of Lactobacilli Species Isolated from Children’s Feces. Anaerobe 2013, 24, 36–42. [Google Scholar] [CrossRef] [PubMed]
  97. Vlková, E.; Grmanová, M.; Killer, J.; Mrázek, J.; Kopecný, J.; Bunesová, V.; Rada, V. Survival of Bifidobacteria Administered to Calves. Folia Microbiol. 2010, 55, 390–392. [Google Scholar] [CrossRef]
  98. Mulaw, G.; Sisay Tessema, T.; Muleta, D.; Tesfaye, A. In Vitro Evaluation of Probiotic Properties of Lactic Acid Bacteria Isolated from Some Traditionally Fermented Ethiopian Food Products. Int. J. Microbiol. 2019, 2019, 7179514. [Google Scholar] [CrossRef] [Green Version]
  99. FAO; WHO. Guidelines for the Evaluation of Probiotics in Food; World Health Organization: Geneva, Switzerland; Food And Agriculture Organization: Rome, Italy, 2002.
  100. Carvalho, A.S.; Silva, J.; Ho, P.; Teixeira, P.; Malcata, F.X.; Gibbs, P. Relevant Factors for the Preparation of Freeze-Dried Lactic Acid Bacteria. Int. Dairy J. 2004, 14, 835–847. [Google Scholar] [CrossRef]
  101. Geigerová, M.; Vlková, E.; Bunešová, V.; Rada, V. Persistence of Bifidobacteria in the Intestines of Calves after Administration in Freeze-Dried Form or in Fermented Milk. Czech J. Anim. Sci. 2016, 61, 49–57. [Google Scholar] [CrossRef] [Green Version]
  102. Darnaud, M.; De Vadder, F.; Bogeat, P.; Boucinha, L.; Bulteau, A.-L.; Bunescu, A.; Couturier, C.; Delgado, A.; Dugua, H.; Elie, C.; et al. A Standardized Gnotobiotic Mouse Model Harboring a Minimal 15-Member Mouse Gut Microbiota Recapitulates SOPF/SPF Phenotypes. Nat. Commun. 2021, 12, 6686. [Google Scholar] [CrossRef]
Table 1. Cultivation media and conditions used for isolation of bacteria from pig samples.
Table 1. Cultivation media and conditions used for isolation of bacteria from pig samples.
Targeted Bacterial GroupsCultivation MediumCultivation Condition
Total anaerobesWilkins–Chalgren agar, 5 g/L soya peptone (both Oxoid), 0.5 g/L L-cysteine, 1 mL/L tween 80 (both Sigma-Aldrich), WSP agar37 °C, 48 h, anaerobiosis
BifidobacteriaWSP agar, 100 mg/L norfloxacin, 100 mg/L mupirocin (both Oxoid), 1 mL/L glacial acetic acid (Sigma-Aldrich) [49] 37 °C, 48 h, anaerobiosis
SporulatesWSP agar/Tryptone Soya agar (Oxoid)37 °C, 48 h, anaerobiosis/aerobiosis; 80 °C for 10 min prior cultivation
LactobacilliRogosa agar (Oxoid), 1.32 mL/L acetic acid (Sigma-Aldrich)37 °C, 72 h, microaerophilic conditions
ColiformsTBX agar (Oxoid)37 °C, 24 h, aerobiosis
Table 2. Bacterial species isolated from colon and fecal samples of pigs and piglets.
Table 2. Bacterial species isolated from colon and fecal samples of pigs and piglets.
Targeted Bacterial GroupsIsolated Bacteria (Number of Isolates)
Total anaerobesAcidaminococcus fermentans (5)Eubacterium tenue (3)
Bacteroides uniformis (9)Mitsuokella mulracida (5)
Enterococcus durans (5)Staphylococcus aureus (6)
Enterococcus faecalis (9)Staphylococcus warneri (3)
Enterococcus faecium (7)Streptococcus alactolyticus (2)
BifidobacteriaBifidobacterium animalis (12)Bifidobacterium pseudolongum (8)
Bifidobacterium apri (3)Bifidobacterium thermophilium (9)
Bifidobacterium boum (9)Mitsuokella mulracida (6)
Bifidobacterium porcinum (12)
SporulatesBacillus amyloliquefaciens (2)Bacillus vallismortis (2)
Bacillus cereus (2)Clostridium cochlearium (3)
Bacillus licheniformis (7)Clostridium perfringens (10)
Bacillus mycoides (8)Clostridium sporogenes (12)
Bacillus paramycoides (5)Paeniclostridium sordellii (8)
Bacillus subtilis (8)Paraclostridium bifermentans (4)
Bacillus thuringiensis (1)Terrisporobacter glycolicus (1)
LactobacilliLacticaseibacillus paracasei (5)Lactobacillus porci (8)
Lactobacillus amylovorus (17)Ligilactobacillus agilis (2)
Lactobacillus antri (2)Ligilactobacillus ruminis (10)
Lactobacillus delbrueckii (2)Ligilactobacillus salivarius (3)
Lactobacillus fermentum (2)Limosilactobacillus mucosae (4)
Lactobacillus johnsonii (5)Limosilactobacillus reuteri (18)
Lactobacillus kitasatonis (2)
ColiformsEscherichia fergusonii (3)Shigella flexneri (4)
Escherichia coli (11)
Table 3. Identification and functional properties of commensal bacteria isolated from pig and piglet colon and fecal sample.
Table 3. Identification and functional properties of commensal bacteria isolated from pig and piglet colon and fecal sample.
Delta log CFU/mL Decrease after Incubation in
pH 31.5% Bile Inhibition Zones (mm) *
StrainIdentification by 16S rRNA Gene SequencingGenBank Origin1 h2 h2 h3 hLT2STMAggAgg% **Adhesion **
PG1Bacillus paramycoides/paranthracis/nitratireducensOP778050domestic pig colon0.750.970.260.446.00 ± 0.006.00 ± 0.00nt0.41 ± 0.19
PG2Bifidobacterium animalis subsp. lactis OP778043domestic pig feces0.170.190.000.107.67 ± 0.588.33 ± 0.58+ 73.66 ± 1.5317.42 ± 2.22
PG3Bifidobacterium porcinumOP778042domestic pig feces0.060.170.150.169.00 ± 0.008.00 ± 0.00+ 41.07 ± 3.100.17 ± 0.08
PG4Clostridium sporogenesOP778045domestic pig colon0.030.070.110.137.33 ± 0.587.00 ± 0.00+ 24.37 ± 1.520.41 ± 0.10
PG5Lactobacillus paracasei subsp. tolerans OP778044domestic pig colon0.070.210.060.3313.00 ± 0.008.33 ± 0.58+ 61.27 ± 3.612.29 ± 0.46
PG6Lactobacillus amylovorusOP778047wild pig colon0.190.230.450.7910.00 ± 0.008.67 ± 0.58+ 21.83 ± 2.220.27 ± 0.03
PG7Limosilactobacillus reuteri subsp. porcinus OP778046wild pig colon0.030.130.010.019.00 ± 0.0010.67 ± 0.58+ 54.57 ± 2.301.13 ± 0.64
PG8Limosilactobacillus reuteri subsp. suisOP778049domestic pig feces0.110.140.070.118.33 ± 0.5810.00 ± 0.00+ 55.80 ± 0.441.63 ± 0.75
PG9Limosilactobacillus reuteri subsp. porcinusOP778048domestic piglet colon0.010.320.050.087.67 ± 0.587.33 ± 0.58+ 32.33 ± 1.330.74 ± 0.36
* Susceptibility of Salmonella strains to cell-free supernatant of pig origin commensals (diameters are means of three determination ± SD, diameter of the well = 6.00 mm); ** n = 3, mean ± SD; LT2-S. typhimurium; STM—S. typhimurium; Agg—auto-aggregation (scored positive when clearly visible sand-like particles were formed); Agg%—auto-aggregation %; nt—not tested.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Horvathova, K.; Modrackova, N.; Splichal, I.; Splichalova, A.; Amin, A.; Ingribelli, E.; Killer, J.; Doskocil, I.; Pechar, R.; Kodesova, T.; et al. Defined Pig Microbiota with a Potential Protective Effect against Infection with Salmonella Typhimurium. Microorganisms 2023, 11, 1007. https://doi.org/10.3390/microorganisms11041007

AMA Style

Horvathova K, Modrackova N, Splichal I, Splichalova A, Amin A, Ingribelli E, Killer J, Doskocil I, Pechar R, Kodesova T, et al. Defined Pig Microbiota with a Potential Protective Effect against Infection with Salmonella Typhimurium. Microorganisms. 2023; 11(4):1007. https://doi.org/10.3390/microorganisms11041007

Chicago/Turabian Style

Horvathova, Kristyna, Nikol Modrackova, Igor Splichal, Alla Splichalova, Ahmad Amin, Eugenio Ingribelli, Jiri Killer, Ivo Doskocil, Radko Pechar, Tereza Kodesova, and et al. 2023. "Defined Pig Microbiota with a Potential Protective Effect against Infection with Salmonella Typhimurium" Microorganisms 11, no. 4: 1007. https://doi.org/10.3390/microorganisms11041007

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop